Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Lifesciences’ Sapien

This article was originally published in The Gray Sheet

Executive Summary

Sales of the transcatheter aortic heart valve, primarily in Europe, are on-pace to surpass the $50 million mark in 2008, the firm says during its Oct. 22 third-quarter earnings call. "Continued clinician enthusiasm" and the addition of about 20 more implanting centers, on top of the 50 already using Sapien, drove procedures and sales during the quarter, CEO Michael Mussallem said. About 400 of the valves were implanted during the quarter, generating sales of $13 million. In July, the company projected Sapien sales would be $45 million-$50 million for the year; the device gained a CE mark in September 2007 (1"The Gray Sheet" July 28, 2008, p. 8)
Advertisement

Related Content

Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Advertisement
UsernamePublicRestriction

Register

MT026713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel